EU: PRIME Success For Givlaari At CHMP
EMA Panel Recommends Alnylam’s Givosiran For Approval
Interaction with the European Medicines Agency on Givlaari helped Alnylam prepare a more robust application package to demonstrate the medicine’s benefits and risks.
